ARC Pharmaceuticals Inc., of Vancouver, was granted U.S. Patent No. 6,812,220, titled "Pharmaceutical Compositions and Methods Relating to Fucans." The patent protects property licensed to ARC that might be used in the development of its lead product candidates to treat surgical adhesions.
Bioniche Life Sciences Inc., of Belleville, Ontario, was granted U.S. Patent No. 6,890,911, titled "Method for the treatment of inflammation," relating to its core mycobacterial cell wall technology. The patent covers the Mycobacterial Cell Wall-DNA Complex, which has been shown to possess immunomodulatory, vaccine adjuvant and chemotherapeutic activities.
BioVisioN AG, of Hanover, Germany, received a patent, "Differential Peptide Display," covering its core technology for the discovery and identification of peptide biomarkers.
Chimeracom LLC, of New York, was granted U.S. Patent No. 6,881,829 for the invention of Chimeric Hybrid Analgesics, covering composition of matter for, and methods of, treating pain using conjugate molecules.
Ciphergen Biosystems Inc., of Fremont, Calif., was granted U.S. Patent No. 6,844,165 for the detection of multiple diagnostic markers by SELDI-TOF-MS for the diagnosis of disease. The patent relates to multi-marker assays using the company's SELDI ProteinChip System to develop diagnostic tests.
ExonHit Therapeutics SA, of Paris, was awarded U.S. Patent No. 6,881,571, covering microarray products allowing the specific detection of mRNAs produced by alternative splicing. The patent protects the probe configuration of a set of five oligonucleotides for the detection of each splice variant.
FzioMed Inc., of San Lius Obispo, Calif., was granted U.S. Patent No. 6,869,938, covering compositions of polyacids and polyethers, and methods for their use in reducing post-surgical adhesions.
Gen-Probe Inc., of San Diego, was issued U.S. Patent No. 6,890,742, which broadly claims an automated process for isolating and amplifying a target nucleic acid sequence within a closed system.
Helix BioMedix Inc., of Bothell, Wash., was issued U.S. Patent No. 6,875,744, titled "Short Bioactive Peptides." The patent covers the composition of matter and use for peptides of five to 22 amino acids in length that consist, in large part, of four specific amino acids.
Heska Corp., of Fort Collins, Colo., was issued U.S. Patent No. 6,887,672 B2, which covers the use of equine FceRIa molecules to detect IgE, as well as U.S. Patent No. 6,889,145 B1, which covers the use of the structural coordinates of a three-dimensional IgE antibody crystal to identify molecules that inhibit binding between IgE and its receptor.
Imcor Pharmaceutical Co., of San Diego, received a notice of allowance for a patent directed to the composition of matter of forming stabilized microbubbles using mixed gases. Imcor uses this technology for ultrasound contrast enhancement.
Immtech International Inc., of Vernon Hills, Ill., received U.S. Patent No. 6,867,227, titled "Compounds that Exhibit Specific Molecular Recognition of Mixed Nucleic Acid Sequences and Bind the DNA Minor Groove as a Dimer." It covers the potential use of Immtech's compounds as small-molecule drugs that can selectively control gene expression.
Marc Pharmaceuticals Inc., of Stamford, Conn., was granted U.S. Patent No. 6,890,533 for betulinol derivatives licensed from Cornell Research Foundation. The patent covers a range of betulinol derivatives, betulinol/antibody conjugates and methods for making these compounds, which the company is developing to treat cancer.
Maxim Pharmaceuticals Inc., of San Diego, was granted U.S. Patent No. 6,828,091, titled "Method of Identifying Immunosuppressive Agents," which covers a method for identifying agents by screening for compounds that induce apoptosis in activated T or B cells.
MethylGene Inc., of Montreal, was granted U.S. Patent No. 6,884,791, titled "Novel Inhibitors of Beta-Lactamase," which provides protection for compounds and methods of treating bacterial infections.
Nanogen Inc., of San Diego, received U.S. Patent No. 6,884,584, titled "Hybridization and Mismatch Discrimination Using Oligonucleotides Conjugated to Minor Groove Binders," covering the use of Nanogen's MGB probes on traditional solid phase support. The company also was granted U.S. Patent No. 6,887,362, titled "Dielectrophoretic Separation and Immunoassay Methods on Active Electronic Matrix Devices," relating to devices and methods for performing active, multi-step molecular and biological sample preparation.
OSI Pharmaceuticals Inc., of Melville, N.Y., has received a notice of allowance for a patent covering its lead c-Kit/KDR compound, OSI-930. The patent will cover the compound, compositions containing the compound and methods of treating cancers using the compound.
Peplin Ltd., of Brisbane, Australia, was granted a patent covering the use of its macrocyclic cancer compounds to stimulate the immune system. Peplin said the compounds have a combined immune system stimulation and direct cytotoxic effect.
Seattle Genetics Inc., of Bothell, Wash., was granted U.S. Patent No. 6,884,869, covering the compound monomethyl auristatin E and its variants, which the company uses with its linker technology to develop ADCs.
Targeted Genetics Corp., of Seattle, was issued U.S. Patent No. 6,887,463, titled "Methods and Compositions for Gene Therapy for the Treatment of Defects in Lipoprotein Metabolism," covering the adenovirus AAV hybrid vectors encoding the receptor for very low density lipoprotein. The company also was granted U.S. Patent No. 6,893,865, titled "Methods, Compositions and Cells for Encapsidating Recombinant Vectors in AAV Particles," which expands its AAV vector systems used for gene delivery.
Unigen Pharmaceuticals Inc., of Lacey, Wash., received a patent for its antioxidant ingredients contained in the Aloewhite and Pervarin commercial raw material ingredient products derived from the aloe chromone molecule.